Infectious Disease In vitro Diagnostics Market: Growth, Trends, and...

Infectious Disease In vitro Diagnostics Market: Growth, Trends, and Future Outlook to 2031

Posted 2026-04-24 10:52:05

The Infectious Disease In vitro Diagnostics Market is projected to grow from US$ 45.69 billion in 2024 to US$ 76.71 billion by 2031, registering a CAGR of 7.7 percent during the forecast period 2025 to 2031. This steady growth highlights the increasing reliance on in vitro diagnostic solutions for effective disease detection and management across hospitals, diagnostic laboratories, and research institutions. Technological integration, including PCR-based testing, immunoassays, and next-generation sequencing, is further strengthening market performance worldwide.

The global Infectious Disease In vitro Diagnostics Market is experiencing strong expansion, driven by rising disease burden, rapid technological advancements, and increasing demand for early and accurate diagnosis. According to industry analysis, the Infectious Disease In vitro Diagnostics Market Drivers include growing prevalence of infectious diseases, expansion of point-of-care testing, and advancements in molecular diagnostic technologies, all of which are significantly shaping global healthcare outcomes.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00040978

Market Overview and Key Growth Factors

The Infectious Disease In vitro Diagnostics market plays a critical role in identifying pathogens such as viruses, bacteria, and parasites using biological samples like blood and tissue. The rising incidence of diseases such as tuberculosis, HIV, hepatitis, and emerging viral infections has increased the need for faster and more reliable diagnostic tools.

One of the major market trends is the shift toward rapid and point-of-care diagnostics, which enables immediate clinical decision-making. In addition, increased investment in healthcare infrastructure, especially in developing regions, is boosting the adoption of advanced diagnostic systems. Post-pandemic awareness has also led governments to prioritize early disease detection and surveillance systems, further supporting market expansion.

Technological innovation remains a central driver, with automation, artificial intelligence, and molecular diagnostics improving accuracy and efficiency. These developments are reducing turnaround times and enabling large-scale screening programs across populations.

Key Market Drivers

The market is primarily driven by several interconnected factors:

· Rising global burden of infectious diseases

· Increasing demand for early and accurate disease detection

· Technological advancements in molecular diagnostics and immunoassays

· Growth of point-of-care and home-based testing solutions

· Expanding healthcare infrastructure in emerging economies

· Government initiatives for disease surveillance and public health preparedness

These drivers collectively strengthen the demand for advanced diagnostic platforms, ensuring continuous market growth over the forecast period.

Market Segmentation Insights

The Infectious Disease In vitro Diagnostics market is segmented based on application, end user, and geography. Among applications, hepatitis B and C, tuberculosis, and HIV diagnostics account for a significant share due to their high global prevalence. Hospitals and diagnostic laboratories remain the leading end users, supported by increasing patient inflow and routine testing requirements.

Regionally, North America dominates the market due to advanced healthcare systems and high adoption of innovative technologies. However, Asia Pacific is expected to witness the fastest growth owing to increasing healthcare investments and rising disease prevalence.

Competitive Landscape

The market is highly competitive with the presence of several global leaders focusing on innovation, partnerships, and product expansion. Key players include:

· Abbott Laboratories

· F. Hoffmann-La Roche Ltd.

· Becton, Dickinson and Company

· bioMérieux SA

· Bio-Rad Laboratories Inc.

· QIAGEN N.V.

· Sysmex Corporation

· Danaher Corporation

· QuidelOrtho Corporation

· Bruker Corporation

These companies are actively investing in research and development to introduce advanced diagnostic platforms and strengthen their global market presence.

Future Outlook

The future of the Infectious Disease In vitro Diagnostics market is expected to be shaped by precision medicine, digital diagnostics, and AI-powered laboratory systems. Increasing focus on personalized healthcare and predictive diagnostics will further enhance market opportunities. With a projected value of US$ 76.71 billion by 2031, the sector is poised for sustained growth supported by innovation and global health priorities.

Trending Reports:

· In Vitro Lung Models Market Overview, Growth, Trends, Analysis, Research Report

· In Vitro Diagnostic (IVD) Quality Control Market Growth, Size, Share, Forecast till 2034

· In Vitro Toxicology Testing Market Strategies, Top Players, Growth, Forecast by 2031

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.